In vitro and in vivo activities of sitafloxacin against Chlamydia spp

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3270-3272

  Miyashita, N ^a   Niki, Y ^a   Matsushima, T ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; OFLOXACIN; SITAFLOXACIN; TOSUFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; CONTROLLED STUDY; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

ANIMALS; ANTI-INFECTIVE AGENTS; CHLAMYDIA; CHLAMYDIA INFECTIONS; FLUOROQUINOLONES; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN;

EID: 0034769890     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3270-3272.2001     Document Type: Article

References (17)

1. In vitro activities of five quinolones against Chlamydia pneumoniae
2. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae
3. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae
4. Method for in vitro determination of chlamydial susceptibility (minimum inhibitory concentration; MIC) to antimicrobial agents. Standard method of Japan Society of Chemotherapy (revision in 1991)
5. Method for in vitro determination of chlamydial susceptibility (minimal lethal concentration; MLC) to antimicrobial agents. Standard method of Japan Society of Chemotherapy (revision in 1991)
6. Chlamydia pneumoniae (TWAR)
7. A simplified method of evaluating dose-effect experiments
8. 50 and its error by means of logarithmic-probit graph
9. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
10. Etiology of community-acquired pneumonia in Japan
11. In vitro antibacterial activity of DU-6859a; a new fluoroquinolone
12. Preliminary report on DU-6859a for lower respiratory infection
13. In vitro activities of OPC-17116, a new quinolone, ofloxacin, and sparfloxacin against Chlamydia pneumoniae
14. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae
15. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates
16. Clinical study on sparfloxacin in the treatment of chlamydial respiratory infections
17. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method